Comparison in the Glucose Response of Flexible Liposomes Loaded with Insulin with the Addition of Different Surfactants in an Experimental Diabetes Model

Sara    Melisa    Arciniegas; Sergio    Andres    Saavedra; Danaé      Balderas; Sara       del Carmen Caballero; María    Josefa    Bernad; Julio    Cesar    Sánchez; María    Isabel    Gracia; Héctor    Ariel    Rico; Dinorah       Vargas

doi:10.2174/1570180816666191024102231

Abstract

Background: Insulin has been included in a variety of dosage forms; nevertheless, liposomes have shown protection to degradation and better absorption. The addition of surfactant to liposomes could give the ability to deform and pass through intact membranes, and could increase the stability and the release of the drug.

Introduction: Due to the limitations of the current treatment of insulin in diabetic patients, investigation in alternatives routes has increased. The oral route is the most convenient because of the similarity with the natural secretion of this hormone. The aim was to evaluate the in-vivo effect of fourteen formulations of Insulin-loaded flexible liposomes with different surfactants by oral and subcutaneous routes.

Methods: Fourteen formulations of insulin were obtained with the addition of different surfactants. Size distribution, polydispersion index and Z potential were obtained for all formulations. In-vivo tests were performed in rats induced with experimental diabetes with streptozotocin, and glucose curves were obtained during 480 minutes.

Results: All formulations by the subcutaneous route caused an optimal reduction in glucose levels. However, the addition of Brij L23 produced a better reduction, lasting for 420 minutes. By the oral route, the reduction of glucose did not reach the normal levels, but the addition of Poloxamer 407 and Brij S10 showed the best reduction in the glucose levels by this route.

Conclusion: The addition of surfactants to the lipid structure can modify the release of the insulin by different routes of administration, but this behavior depends on the characteristics of the surfactant, such as the melting phase transition temperature of the lipid bilayer.

Keywords: Tensoactive, insulin, lipid vesicles, diabetes, nanocarrier, liposome.

« Previous Next »

Graphical Abstract

[1] 
Peppas NA, Kavimandan NJ. Nanoscale analysis 
of protein and peptide absorption: insulin absorption using complexation
 and pH-sensitive hydrogels as delivery vehicles. Eur J Pharm Sci  2006;
 29(3-4): 183-97.
[http://dx.doi.org/10.1016/j.ejps.2006.04.014] [PMID: 16777391] 
[2] 
Mahato RI, Narang AS, Thoma L, Miller DD. 
Emerging trends in oral delivery of peptide and protein drugs. Crit Rev 
Ther Drug Carrier Syst  2003; 20(2-3): 153-214.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v20.i23.30] [PMID: 14584523] 
[3] 
Yun Y, Cho YW, Park K. Nanoparticles for oral 
delivery: targeted nanoparticles with peptidic ligands for oral protein 
delivery. Adv Drug Deliv Rev  2013; 65(6): 822-32.
[http://dx.doi.org/10.1016/j.addr.2012.10.007] [PMID: 23123292] 
[4] 
Cevc G, Gebauer D, Stieber J, Schätzlein A, 
Blume G. Ultraflexible vesicles, Transfersomes, have an extremely low 
pore penetration resistance and transport therapeutic amounts of insulin
 across the intact mammalian skin. Biochim Biophys Acta  1998; 1368(2): 
201-15.
[http://dx.doi.org/10.1016/S0005-2736(97)00177-6] [PMID: 9459598] 
[5] 
Malakar J, Sen SO, Nayak AK, Sen KK. 
Formulation, optimization and evaluation of transferosomal gel for 
transdermal insulin delivery. Saudi Pharm J  2012; 20(4): 355-63.
[http://dx.doi.org/10.1016/j.jsps.2012.02.001] [PMID: 23960810] 
[6] 
Fazel M, Daeihameda M, Osoulia M, Almasia A, 
Haeria A, Dadashzadeha S. Preparation, In-Vitro Characterization and 
Pharmacokinetic Evaluation of Brij Decorated Doxorubicin Liposomes as a 
Po-tential Nanocarrier for Cancer Therapy. Iran. J. Pharm. Res, 2018; 
17(Special Issue 2): 33-43.
[7] 
Sonia T, Sharma C. Oral insulin delivery.  1st ed. Woodhead Publishing United Kingdom In:  2014.
[8] 
Cevc G, Schätzlein A, Richardsen H. 
Ultradeformable lipid vesicles can penetrate the skin and other 
semi-permeable barriers unfragmented. Evidence from double label CLSM 
experiments and direct size measurements. Biochim Biophys Acta  2002; 
1564(1): 21-30.
[http://dx.doi.org/10.1016/S0005-2736(02)00401-7] [PMID: 12100992] 
[9] 
Mezei M. Liposomes and the skinLiposomes in 
drug delivery; Gregoridadis, G; Florence, AT Patel, H, Eds; Harwood 
Academic Publishers:.  Switzerland 1993; pp. 24-135.
[10] 
Cevc G, Blume G. New, highly efficient 
formulation of diclofenac for the topical, transdermal administration in
 ultradeformable drug carriers, Transfersomes. Biochim Biophys Acta  
2001; 1514(2): 191-205.
[http://dx.doi.org/10.1016/S0005-2736(01)00369-8] [PMID: 11557020] 
[11] 
Cevc G. Transdermal drug delivery of insulin with ultradeformable carriers. Clin Pharmacokinet  2003; 42(5): 461-74.
[http://dx.doi.org/10.2165/00003088-200342050-00004] [PMID: 12739984] 
[12] 
Rajan R, Jose S, Mukund VP, Vasudevan DT. 
Transferosomes - A vesicular transdermal delivery system for enhanced 
drug permeation. J Adv Pharm Technol Res  2011; 2(3): 138-43.
[http://dx.doi.org/10.4103/2231-4040.85524] [PMID: 22171309] 
[13] 
Arciniegas S. M: Bernad, M.J.; Lopez, R.; 
Torres, R.; Caballero, S.C.; Vargas, D. In-vitro and In-vivo Profiles 
and Characterization of Insulin Nanocarriers Based in Flexible Liposomes
 Designed for Oral Administration. Lett Drug Des Discov  2019; 16(1)
[14] 
Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett  2005; 10(4): 711-9.
[PMID: 16341279] 
[15] 
Park SJ, Choi SG, Davaa E, Park JS. 
Encapsulation enhancement and stabilization of insulin in cationic 
liposomes. Int J Pharm  2011; 415(1-2): 267-72.
[http://dx.doi.org/10.1016/j.ijpharm.2011.05.061] [PMID: 21645598] 
[16] 
Szkudelski T. The mechanism of alloxan and 
streptozotocin action in B cells of the rat pancreas. Physiol Res  2001;
 50(6): 537-46.
[PMID: 11829314] 
[17] 
Trinder P. Determination of glucose in blood 
using glucose oxidase with an alternative oxygen receptor. Ann Clin 
Biochem  1969; 6: 24-37.
[http://dx.doi.org/10.1177/000456326900600108] 
[18] 
 Malvern. Technical Notes [Online]. Malvern Instruments Lim-ited. http://www.malvern.com/en/support/resource-center/technical-notes/TN101104IntensityVolumeNumber.aspx
[19] 
 Wriedt, T. Mie Theory, A review. InThe Mie 
Theory. Basics and applications. Germany, Springer Series in Optical 
Science; Hergert, W.; Wriedt, T., Eds.; 2012, 169, pp. 53-79. In: 
[20] 
Badran M. Formulation and in vitro evaluation 
of flufenamic acid loaded deformable liposome for improved skin 
delivery. Dig J Nanomater Biostruct  2014; 9: 83-91.
[21] 
Chen M, Liu X, Fahr A. Skin penetration and 
deposition of carboxyfluorescein and temoporfin from different lipid 
vesicular systems: In vitro study with finite and infinite dosage 
application. Int J Pharm  2011; 408(1-2): 223-34.
[http://dx.doi.org/10.1016/j.ijpharm.2011.02.006] [PMID: 21316430] 
[22] 
Putri DC, Dwiastuti R, Marchaban M, Nugroho 
AK. Optimization of mixing temperature and sonication duration in 
liposome preparation. J Pharm Sci Commun  2017; 14: 79-85.
[http://dx.doi.org/10.24071/jpsc.142728] 
[23] 
Patel HM, Ryman BE. Oral administration of insulin by encapsulation within liposomes. FEBS Lett  1976; 62(1): 60-3.
[http://dx.doi.org/10.1016/0014-5793(76)80016-6] [PMID: 129340] 
[24] 
Spangler RS. Insulin administration via liposomes. Diabetes Care  1990; 13(9): 911-22.
[http://dx.doi.org/10.2337/diacare.13.9.911] [PMID: 2226109] 
[25] 
Choudhari KB, Labhasetwar V, Dorle AK. 
Liposomes as a carrier for oral administration of insulin: effect of 
formulation factors. J Microencapsul  1994; 11(3): 319-25.
[http://dx.doi.org/10.3109/02652049409040461] [PMID: 8064555] 
[26] 
Mustata G, Dinh SM. Approaches to oral drug 
delivery for challenging molecules. Crit Rev Ther Drug Carrier Syst  
2006; 23(2): 111-35.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v23.i2.20] [PMID: 16952274] 
[27] 
Bendayan M, Ziv E, Gingras D, Ben-Sasson R, 
Bar-On H, Kidron M. Biochemical and morpho-cytochemical evidence for the
 intestinal absorption of insulin in control and diabetic rats. 
Comparison between the effectiveness of duodenal and colon mucosa. 
Diabetologia  1994; 37(2): 119-26.
[http://dx.doi.org/10.1007/s001250050081] [PMID: 8163044] 
[28] 
Khan MA, Agarwal V. Composition and method for
 preparation of an oral dual con-trolled release formulation of a 
protein and inhibitor. US Patent, 2003, 20, 220-254
                     
[29] 
TenHoor C, Dressman J. Oral absorption of peptides and proteins. STP Pharma Sci  1992; 2: 301-12.
[30] 
Patel HM, Stevenson RW, Parsons JA, Ryman BE. 
Use of liposomes to aid intestinal absorption of entrapped insulin in 
normal and diabetic dogs. Biochim Biophys Acta  1982; 716(2): 188-93.
[http://dx.doi.org/10.1016/0304-4165(82)90267-7] [PMID: 7046805] 
[31] 
Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med  2003; 20(11): 886-98.
[http://dx.doi.org/10.1046/j.1464-5491.2003.01076.x] [PMID: 14632713] 
[32] 
Lai SK, Wang YY, Hanes J. Mucus-penetrating 
nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug 
Deliv Rev  2009; 61(2): 158-71.
[http://dx.doi.org/10.1016/j.addr.2008.11.002] [PMID: 19133304] 
[33] 
Değim IT, Gümüşel B, Değim Z, Ozçelikay T, Tay
 A, Güner S. Oral administration of liposomal insulin. J Nanosci 
Nanotechnol  2006; 6(9-10): 2945-9.
[http://dx.doi.org/10.1166/jnn.2006.416] [PMID: 17048502] 
[34] 
Sipai Altaf Bhai M, Vandana D, Mamatha Y, Prasanth V. Liposomes:An overview. J Pharm Sci Innov  2012; 1(1): 13-21.
[35] 
Vijayakumar M, Kosuru R, Vuddanda P, Singh KS,
 Singh S. Trans resveratrol loaded DSPE PEG 2000 coated liposomes: An 
evidence for prolonged systemic circulation and passive brain targeting.
 J Drug Deliv Sci Technol  2016; 33: 125-35.
[http://dx.doi.org/10.1016/j.jddst.2016.02.009] 
[36] 
www.biophysics.bioc.cam.ac.uk/wp-content/uploads/2011/02/DLS_Terms_defined_Malvern.pdf
[37] 
Martins S, Sarmento B, Ferreira DC, Souto EB. 
Lipid-based colloidal carriers for peptide and protein 
delivery--liposomes versus lipid nanoparticles. Int J Nanomedicine  
2007; 2(4): 595-607.
[PMID: 18203427] 
[38] 
Zhang P, Huang Y, Makhov AM, Gao X, Zhang P, 
Li S. Characterization of spherulites as a lipidic carrier for low and 
high molecular weight agents. Pharm Res  2013; 30(6): 1525-35.
[http://dx.doi.org/10.1007/s11095-013-0990-y] [PMID: 23579481] 
[39] 
Kneidl B, Peller M, Winter G, Lindner LH, 
Hossann M. Thermosensitive liposomal drug delivery systems: state of the
 art review. Int J Nanomedicine  2014; 9: 4387-98.
[PMID: 25258529] 
[40] 
Tagami T, Ernsting MJ, Li SD. Optimization of a
 novel and improved thermosensitive liposome formulated with DPPC and a 
Brij surfactant using a robust in vitro system. J Control Release  2011;
 154(3): 290-7.
[http://dx.doi.org/10.1016/j.jconrel.2011.05.020] [PMID: 21640149] 
[41] 
Thakur R, Das A, Chakraborty A. The fate of 
anticancer drug, ellipticine in DPPC and DMPC liposomes upon interaction
 with HSA: a photophysical approach. J Photochem Photobiol B  2014; 
130(5): 122-31.
[http://dx.doi.org/10.1016/j.jphotobiol.2013.10.016] [PMID: 24322006] 
[42] 
Tian JL, Ke X, Chen Z, Wang CJ, Zhang Y, Zhong
 TC. Melittin liposomes surface modified with poloxamer 188: in vitro 
characterization and in vivo evaluation. Pharmazie  2011; 66(5): 362-7.
[PMID: 21699070] 
[43] 
Grohmann F, Csempesz F, Szogyi M. 
Stabilization of small unilamellar DMPC-liposomes by uncharged polymers.
 Colloid Polym Sci  1998; 276: 66-71.
[http://dx.doi.org/10.1007/s003960050210] 
[44] 
Zhang W, Wang G, See E, et al. Shaw, 
J.P.; Baguley, B.C.; Liu, J.; Amirapu, S.; Wu, Z. Post-insertion of 
poloxamer 188 strengthened liposomal membrane and reduced drug irritancy
 and in vivo precipitation, superior to PEGylation. J Control Release  
2015; 203: 161-9.
[http://dx.doi.org/10.1016/j.jconrel.2015.02.026] [PMID: 25701612] 
[45] 
Lasic DD. Liposomes from physics to applications.  1st ed. ElSevier Science BV Amsterdam 1993.
[46] 
Mozafari MR, Reed CJ, Rostron C. Cytotoxicity 
evaluation of anionic nanoliposomes and nanolipoplexes prepared by the 
heating method without employing volatile solvents and detergents. 
Pharmazie  2007; 62(3): 205-9.
[PMID: 17416197] 
[47] 
Arciniegas SM, Bernad MJ, Caballero S, Vargas 
D. Glucose Response in Animals Induced with experimental Diabetes Type 1
 after Treatment with Human Insulin Exposed To High Temperatures. 
Transylv Rev  2017; XXV(23): 6191-6.

Rights & Permissions Print Cite

Article Metrics

35

Explore Articles

Open Access

Open Access Articles

DOI https://dx.doi.org/10.2174/1570180816666191024102231	Print ISSN 1570-1808
Publisher Name Bentham Science Publisher	Online ISSN 1875-628X

Letters in Drug Design & Discovery

Comparison in the Glucose Response of Flexible Liposomes Loaded with Insulin with the Addition of Different Surfactants in an Experimental Diabetes Model

Abstract Play Pause

Graphical Abstract

Related Articles

Abstract